171 related articles for article (PubMed ID: 29720713)
1. Treatment resistance in urothelial carcinoma: an evolutionary perspective.
Vlachostergios PJ; Faltas BM
Nat Rev Clin Oncol; 2018 Aug; 15(8):495-509. PubMed ID: 29720713
[TBL] [Abstract][Full Text] [Related]
2. Clonal evolution of chemotherapy-resistant urothelial carcinoma.
Faltas BM; Prandi D; Tagawa ST; Molina AM; Nanus DM; Sternberg C; Rosenberg J; Mosquera JM; Robinson B; Elemento O; Sboner A; Beltran H; Demichelis F; Rubin MA
Nat Genet; 2016 Dec; 48(12):1490-1499. PubMed ID: 27749842
[TBL] [Abstract][Full Text] [Related]
3. Commentary on: "Clonal evolution of chemotherapy-resistant urothelial carcinoma." Faltas BM, Prandi D, Tagawa ST, Molina AM, Nanus DM, Sternberg C, Rosenberg J, Mosquera JM, Robinson B, Elemento O, Sboner A, Beltran H, Demichelis F, Rubin MA.: Nat Genet. 2016 Oct 17. http://dx.doi.org/10.1038/ng.3692.
Lee BH
Urol Oncol; 2017 Sep; 35(9):577-578. PubMed ID: 28780131
[TBL] [Abstract][Full Text] [Related]
4. Treatment-Induced Mutagenesis and Selective Pressures Sculpt Cancer Evolution.
Venkatesan S; Swanton C; Taylor BS; Costello JF
Cold Spring Harb Perspect Med; 2017 Aug; 7(8):. PubMed ID: 28289245
[TBL] [Abstract][Full Text] [Related]
5. Tumour heterogeneity and resistance to cancer therapies.
Dagogo-Jack I; Shaw AT
Nat Rev Clin Oncol; 2018 Feb; 15(2):81-94. PubMed ID: 29115304
[TBL] [Abstract][Full Text] [Related]
6. Harnessing Tumor Evolution to Circumvent Resistance.
Pogrebniak KL; Curtis C
Trends Genet; 2018 Aug; 34(8):639-651. PubMed ID: 29903534
[TBL] [Abstract][Full Text] [Related]
7. Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia.
Oshima K; Khiabanian H; da Silva-Almeida AC; Tzoneva G; Abate F; Ambesi-Impiombato A; Sanchez-Martin M; Carpenter Z; Penson A; Perez-Garcia A; Eckert C; Nicolas C; Balbin M; Sulis ML; Kato M; Koh K; Paganin M; Basso G; Gastier-Foster JM; Devidas M; Loh ML; Kirschner-Schwabe R; Palomero T; Rabadan R; Ferrando AA
Proc Natl Acad Sci U S A; 2016 Oct; 113(40):11306-11311. PubMed ID: 27655895
[TBL] [Abstract][Full Text] [Related]
8. Molecular basis of clonal evolution in multiple myeloma.
Furukawa Y; Kikuchi J
Int J Hematol; 2020 Apr; 111(4):496-511. PubMed ID: 32026210
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies.
Ross JS; Ali SM; Wang K; Palmer G; Yelensky R; Lipson D; Miller VA; Zajchowski D; Shawver LK; Stephens PJ
Gynecol Oncol; 2013 Sep; 130(3):554-9. PubMed ID: 23791828
[TBL] [Abstract][Full Text] [Related]
10. Roles of tumor heterogeneity in the development of drug resistance: A call for precision therapy.
Wu D; Wang DC; Cheng Y; Qian M; Zhang M; Shen Q; Wang X
Semin Cancer Biol; 2017 Feb; 42():13-19. PubMed ID: 27840278
[TBL] [Abstract][Full Text] [Related]
11. Novel biomarkers in bladder cancer.
Cheng ML; Iyer G
Urol Oncol; 2018 Mar; 36(3):115-119. PubMed ID: 29472156
[TBL] [Abstract][Full Text] [Related]
12. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?
Gandour-Edwards R; Lara PN; Folkins AK; LaSalle JM; Beckett L; Li Y; Meyers FJ; DeVere-White R
Cancer; 2002 Sep; 95(5):1009-15. PubMed ID: 12209684
[TBL] [Abstract][Full Text] [Related]
13. A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
Wang L; Šuštić T; Leite de Oliveira R; Lieftink C; Halonen P; van de Ven M; Beijersbergen RL; van den Heuvel MM; Bernards R; van der Heijden MS
Eur Urol; 2017 Jun; 71(6):858-862. PubMed ID: 28108151
[TBL] [Abstract][Full Text] [Related]
14. Second-line therapy for metastatic urothelial carcinoma: Defining the best treatment option among immunotherapy, chemotherapy, and antiangiogenic targeted therapies. A systematic review and meta-analysis.
Ciccarese C; Iacovelli R; Bria E; Mosillo C; Bimbatti D; Fantinel E; Bisogno I; Brunelli M; Tortora G
Semin Oncol; 2019 Feb; 46(1):65-72. PubMed ID: 30665685
[TBL] [Abstract][Full Text] [Related]
15. Characterizing neoantigens for personalized cancer immunotherapy.
Capietto AH; Jhunjhunwala S; Delamarre L
Curr Opin Immunol; 2017 Jun; 46():58-65. PubMed ID: 28478383
[TBL] [Abstract][Full Text] [Related]
16. Tumor heterogeneity and response to chemotherapy.
Sugino S; Janicki PK
Pharmacogenomics; 2013 Dec; 14(16):1949. PubMed ID: 24279849
[No Abstract] [Full Text] [Related]
17. The State of Immune Checkpoint Inhibition in Urothelial Carcinoma: Current Evidence and Future Areas of Exploration.
Campbell MT; Siefker-Radtke AO; Gao J
Cancer J; 2016; 22(2):96-100. PubMed ID: 27111904
[TBL] [Abstract][Full Text] [Related]
18. Quantitative Clinical Imaging Methods for Monitoring Intratumoral Evolution.
Kim JY; Gatenby RA
Methods Mol Biol; 2017; 1513():61-81. PubMed ID: 27807831
[TBL] [Abstract][Full Text] [Related]
19. Trapping Cancers as They Adapt to Survive.
Haq R
Cancer Discov; 2017 Nov; 7(11):1216-1217. PubMed ID: 29097618
[TBL] [Abstract][Full Text] [Related]
20. Making urothelial carcinomas less immune to immunotherapy.
Ramos JD; Yu EY
Urol Oncol; 2016 Dec; 34(12):534-537. PubMed ID: 27836245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
